First-in-human dose-escalating study of ABSK043, a novel and oral small-molecule inhibitor of PD-L1, in patients with advanced solid tumors

被引：2
|
作者：
Cooper, A. [1 ]
Andelkovic, V. [2 ]
Wilkinson, K. [1 ]
Ganju, V. [3 ]
Lundy, J. [3 ]
Hong, M. [1 ]
Airey, S. [2 ]
Meng, L. L. [4 ]
Shen, B. [5 ]
Li, H. [6 ]
Yao, L. [7 ]
Zhang, M. [3 ,8 ]
Coward, J. [2 ]
机构：
[1] Liverpool Hosp, Dept Med Oncol, South Western Sydney Local Hlth Dist, Liverpool, NSW, Australia
[2] ICON Canc Ctr South Brisbane, Dept Gynaeoncol, Brisbane, Qld, Australia
[3] Peninsula & Southeast Oncol, Dept Oncol, Frankston, Vic, Australia
[4] Abbisko Therapeut Co Ltd, Med Clin, Shanghai, Peoples R China
[5] Abbisko Therapeut Co Ltd, Translat Med, Shanghai, Peoples R China
[6] Abbisko Therapeut Co Ltd, Biometr, Shanghai, Peoples R China
[7] Abbisko Therapeut Co Ltd, Clin Pharmacol, Shanghai, Peoples R China
[8] Abbisko Therapeut Co Ltd, Clin Dev, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1886
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
700P
引用
收藏
页码：S487 / S487
页数：1
相关论文
共 50 条
  • [41] First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors.
    De Bono, Johann Sebastian
    Mina, Lida A.
    Gonzalez, Michael
    Curtin, Nicola J.
    Wang, Evelyn
    Henshaw, Joshua W.
    Chadha, Manpreet
    Sachdev, Jasgit C.
    Matei, Daniela
    Jameson, Gayle S.
    Ong, Michael
    Basu, Bristi
    Wainberg, Zev A.
    Byers, Lauren Averett
    Chugh, Rashmi
    Dorr, Andrew
    Kaye, Stanley B.
    Ramanathan, Ramesh K.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [42] CCX559, an orally administered small molecule PD-L1 inhibitor for the treatment of solid tumors
    Sullivan, Kathleen M.
    Miao, Shichang
    Yue, Huibin
    Zhao, Niky
    Li, Chris
    Tai, Ezra
    Ebsworth, Karen
    Rico, Gonzalo Tapia
    De Souza, Paul
    Schall, Tom
    Zhang, Penglie
    CANCER RESEARCH, 2022, 82 (12)
  • [43] PHASE 1 STUDY OF INCB086550, AN ORAL PD-L1 INHIBITOR, IN IMMUNE-CHECKPOINT NAIVE PATIENTS WITH ADVANCED SOLID TUMORS
    Van Cutsem, Eric
    Prenen, Hans
    Delafontaine, Brant
    Spencer, Kristen
    Mitchell, Tara
    Burris, Howard
    Kotecki, Nuria
    Kristeleit, Rebecca
    Pinato, David
    Sahebjam, Solmaz
    Graham, Donna
    Karasic, Thomas
    Daniel, Jeannie
    O'Hayer, Kevin
    Geschwindt, Ryan
    Piha-Paul, Sarina
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A559 - A560
  • [44] First-in-human phase 1 dose escalation study of the KAT6 inhibitor PF-07248144 in patients with advanced solid tumors
    Sommerhalder, David
    Hamilton, Erika P.
    Mukohara, Toru
    Yonemori, Kan
    Mita, Monica M.
    Yamashita, Toshinari
    Zheng, Jenny
    Liu, Li
    Maity, Arnab K.
    Mishra, Natasha Homji
    Bogg, Orlaith
    Li, Meng
    LoRusso, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [45] First-in-human study of AMG 337, a highly selective oral inhibitor of MET, in adult patients (pts) with advanced solid tumors
    Hong, David S.
    LoRusso, Patricia
    Hamid, Omid
    Beaupre, Darrin M.
    Janku, Filip
    Khan, Rabla
    Kittaneh, Mualad
    Loberg, Robert D.
    Amore, Benny
    Caudillo, Isaac
    Hwang, Yuying C.
    Tang, Rui
    Mgarmchamnanrith, Gataree
    Kwak, Eunice Leo
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [46] First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors
    Brunetto, Andre T.
    Ang, Joo Ern
    Lal, Rohit
    Olmos, David
    Molife, L. Rhoda
    Kristeleit, Rebecca
    Parker, Ann
    Casamayor, Isabel
    Olaleye, Muyibat
    Mais, Anna
    Hauns, Bernhard
    Strobel, Vera
    Hentsch, Bernd
    de Bono, Johann S.
    CLINICAL CANCER RESEARCH, 2013, 19 (19) : 5494 - 5504
  • [47] MEDI5752, a novel PD-1/CTLA-4 bispecific checkpoint inhibitor for advanced solid tumors: First-in-human study
    Tran, Ben
    Voskoboynik, Mark
    Kim, Sang-We
    Lemech, Charlotte
    Carcereny, Enric
    Rha, Sun Young
    Ahn, Myung-Ju
    Felip, Enriqueta
    Lee, Ki H.
    Alvarez, Eduardo C.
    Yang, James Chih-Hsin
    Ascierto, Paolo A.
    Pulla, Mariano P.
    Freeman, Dan
    Song, Xuyang
    Gainer, Shelby D.
    Mitchell, Patrick
    Achour, Ikbel
    Subramaniam, Deepa S.
    Im, Seock-Ah
    CANCER RESEARCH, 2022, 82 (12)
  • [48] First-in-Human Phase I Study of Envafolimab, a Novel Subcutaneous Single-Domain Anti-PD-L1 Antibody, in Patients with Advanced Solid Tumors
    Papadopoulos, Kyriakos P.
    Harb, Wael
    Peer, Cody J.
    Hua, Qiong
    Xu, Siying
    Lu, Haolan
    Lu, Ni
    He, Yue
    Xu, Ting
    Dong, Ruiping
    Gong, John
    Liu, David
    ONCOLOGIST, 2021, 26 (09): : E1514 - E1525
  • [49] Phase 1, first-in-human, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-3654, a PIM kinase inhibitor, in patients with advanced solid tumors
    Garrido-Laguna, Ignacio
    Dillon, Patrick M.
    Kabir, Sujan
    Mei, Jian
    Wade, Mark L.
    Yang, Huyuan
    Stapinski, Carl
    Foulks, Jason M.
    Warner, Steven L.
    Whatcott, Clifford
    Lebedinsky, Claudia
    Fu, Siqing
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [50] First-in-human, first-in-class phase 1 study of a novel oral multi-AGC kinase inhibitor AT13148 in patients (pis) with advanced solid tumors.
    Kumar, Rajiv
    Mateo, Joaquin
    Smith, Alan D.
    Khan, Khurum Hayat
    Ruddle, Ruth
    Swales, Karen E.
    Decordova, Shaun
    Backholer, Zoe
    Jones, Paul
    Tran, Christine
    Seeramraddi, Satyanarayana
    McLeod, Robert
    Yap, Timothy Anthony
    Raynaud, Florence I.
    Garrett, Michelle D.
    Banerji, Udai
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345